Edgen Stock·Nov 19 2025, 06:17返回
返回
艾伯维获得FDA完全批准EPKINLY联合疗法治疗滤泡性淋巴瘤
Edgen Stock·Nov 19 2025, 06:17
[1] 艾伯维宣布美国FDA批准EPKINLY® (epcoritamab ... (https://news.abbvie.com/2025-11-18-AbbVie-Ann ...)[2] FDA批准epcoritamab-bysp用于滤泡性淋巴瘤适应症 (https://www.fda.gov/drugs/resources-informati ...)[3] Epcoritamab联合利妥昔单抗和来那度胺达到两项主要终点... (https://www.onclive.com/view/epcoritamab-plus ...)